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Prosap/Shank scaffolding proteins regulate the formation, organization, and plasticity of excitatory synapses. Mutations in SHANK
family genes are implicated in autism spectrum disorder and other neuropsychiatric conditions. However, the molecular mechanisms
underlying Shank function are not fully understood, and no study to date has examined the consequences of complete loss of all Shank
proteins in vivo. Here we characterize the single Drosophila Prosap/Shank family homolog. Shank is enriched at the postsynaptic mem-
braneof glutamatergic neuromuscular junctions and controlsmultiple parameters of synapse biology in adose-dependentmanner. Both
loss and overexpression of Shank result in defects in synaptic bouton number and maturation. We find that Shank regulates a nonca-
nonical Wnt signaling pathway in the postsynaptic cell by modulating the internalization of the Wnt receptor Fz2. This study identifies
Shank as a key component of synaptic Wnt signaling, defining a novel mechanism for how Shank contributes to synapse maturation
during neuronal development.
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Introduction
The postsynaptic density (PSD) of excitatory synapses contains a
complex and dynamic arrangement of proteins, allowing the cell
to respond to neurotransmitter and participate in bidirectional
signaling to regulate synaptic function (Sheng and Kim, 2011).
Prosap/Shank family proteins are multidomain proteins that
form an organizational scaffold at the PSD. Human genetic stud-
ies have implicated SHANK family genes as causative for autism
spectrum disorder (ASD) (Uchino andWaga, 2013; Guilmatre et
al., 2014), with haploinsufficiency of SHANK3 considered one of
themost prevalent causes (Betancur and Buxbaum, 2013). Inves-
tigations of Shank in animal models have identified several
functions for the protein at synapses, including regulation of glu-
tamate receptor trafficking, the actin cytoskeleton, and synapse
formation, transmission, and plasticity (Grabrucker et al., 2011;
Jiang and Ehlers, 2013). However, phenotypes associated with
loss of Shank are variable, and it has been challenging to fully
remove Shank protein function in vivo as a result of redundancy
between three Shank family genes and the existence of multiple
isoforms of each Shank. There is a single homolog of Shank in
Drosophila (Liebl and Featherstone, 2008), presenting the oppor-
tunity to characterize the function of Shank at synapses in vivo in
null mutant animals.
Wnt pathways play important roles in synaptic development,
function, and plasticity (Dickins and Salinas, 2013). Like Shank
and several other synaptic genes, deletions and duplications of
canonical Wnt signaling components have been identified in in-
dividuals with ASD (Kalkman, 2012). A postsynaptic noncanoni-
cal Wnt pathway has been characterized at the Drosophila
glutamatergic neuromuscular junction (NMJ), linking release of
Wnt by the presynaptic neuron to plastic responses in the post-
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Significance Statement
Haploinsufficiency for SHANK3 is one of themost prevalentmonogenic causes of autismspectrumdisorder,making it imperative
tounderstandhow the Shank family regulates neurodevelopment and synapse function.We created the first animalmodel lacking
all Shank proteins and used the Drosophila neuromuscular junction, a model glutamatergic synapse, to characterize the role of
Shank at synapses.We identified a novel function of Shank in synapsematuration via regulation ofWnt signaling in the postsyn-
aptic cell.
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synaptic cell. In this Frizzled-2 (Fz2) nuclear import (FNI) path-
way, Wnt1/Wg is secreted by the neuron and binds its receptor
Fz2 in the postsynaptic membrane. Surface Fz2 is then internal-
ized and cleaved, and a C-terminal fragment of Fz2 (Fz2-C) is
imported into the nucleus in which it interacts with ribonucleo-
protein particles containing synaptic transcripts (Mathew et al.,
2005; Ataman et al., 2006;Mosca and Schwarz, 2010; Speese et al.,
2012). Mutations in this pathway result in defects of synaptic
development at the NMJ.
We created a null allele of Drosophila Shank, allowing us to
investigate the consequences of removing all Shank protein in
vivo. We show that loss of Shank impairs synaptic bouton num-
ber and maturity and results in defects in the organization of the
subsynaptic reticulum (SSR), a complex system of infoldings of
the postsynaptic membrane at the NMJ. We also demonstrate
that overexpression of Shank has morphological consequences
similar to loss of Shank and that Shank dosage is critical to syn-
aptic development. Finally, our results indicate that Shank regu-
lates the internalization of Fz2 to affect the FNI signaling
pathway, revealing a novel connection between the scaffolding
protein Shank and synaptic Wnt signaling.
Materials andMethods
Drosophila stocks and transgenics.AllDrosophila strains were cultured on
standard media at 25°C. The following stocks were used: mef2–GAL4
[Bloomington Drosophila Stock Center (BDSC) stock #27390; Ranga-
nayakulu et al., 1996], 24B–GAL4 (BDSC stock #1767; Brand and Perri-
mon, 1993), UAS–NLS–GFP (BDSC stock #4776; Shiga et al., 1996),
Df(2R)BSC361 (BDSC stock #24385; Cook et al., 2012),UAS–myc–NLS–
DFz2-C (Mathew et al., 2005), GluRIIB–GFP (Schmid et al., 2008), and
UAS–Fz2–GFP (Chen et al., 2004). Animals of either sex were used.
Full-length Shank cDNA (Drosophila Genomics Resource Center stock
#LD13733; Rubin et al., 2000) was subcloned into pENTR/DTOPO (Life
Technologies). UAS–Shank and UAS–Shank–GFP were generated using
the Gateway system (Invitrogen) to move Shank into destination vectors
pPW and pPWG (Gateway vectors developed by T. Murphy, Carnegie
Institution ofWashington, Baltimore,MD). pPWand pPWGweremod-
ified with the addition of an attB sequence (Groth et al., 2004) at the Nsi1
site. The constructs were injected into a third chromosome docking
strain ( y1 w67c23;P{CaryP}attP2) by Best Gene.
Shank antibody production. A Shank antibody was raised against a
Shank peptide (amino acids 51–148) in rabbit using polyclonal genomic
antibody technology by SDIX.
Shank mutagenesis. The Minos line Mi{ET1}ProsapMB03234 (BDSC
stock #24446; Metaxakis et al., 2005; Bellen et al., 2011) carrying an
insertion in the large first intron of the Shank locus was combined with
the Bloom allele BlmN1 (BDSC stock #28878; McVey et al., 2007) to
produce the stock Mi{ET1}ProsapMB03234;BlmN1/TM6B. The Minos
transposase P[hsILMiT]2.4 (BDSC stock #24613; Metaxakis et al., 2005)
was combined with the Bloom allele BlmD3 (BDSC stock #8656; Boyd et
al., 1981) to produce the stock nocSco/SM6a,P[hsILMiT]2.4;BlmD3/
TM6B. These two stocks were crossed together to mobilize the Minos
insertion in aBlmmutant background as described previously (Witsell et
al., 2010). Approximately 200 GFP-negative candidate lines were tested
by PCR to detect deletions that reached into coding sequences (the end of
the first exon and/or the start of the second exon). ShankD101 was iden-
tified and sequenced to determine the deletion breakpoints (genomic
location of the deleted sequence is 2R:14062907..14074533, FB2015_04).
A precise excision with no deletion was also identified. “Control” in all
figures refers to this precise excision line unless specified otherwise.
Immunostaining. Larvae were reared at 25°C and dissected at the third
wandering instar stage. Larvae were dissected in HL3.1 solution (in mM:
70 NaCl, 5 KCl, 10 NaHCO3, 4 MgCl2, 5 trehalose, 115 sucrose, and 5
HEPES, pH 7.2) and fixed in 4% paraformaldehyde or as indicated oth-
erwise. After washes in PBT (PBS containing 0.3% Triton X-100), larvae
were blocked for 1 h in PBT containing 2%normal goal serum, incubated
overnight with primary antibody at 4°C, washed, incubated with second-
ary antibodies for 2 h at room temperature, washed, and mounted in
Vectashield (Vector Laboratories) for imaging. For Shank stainings,
Shank antibody was preabsorbed on Shank null mutant tissue to reduce
background staining. Antibodies were as follows:mouse anti-Dlg, 1:1000
[Developmental Studies Hybridoma Bank (DSHB) stock #4F3; Parnas et
al., 2001]; mouse anti-Bruchpilot (Brp), 1:500 (DSHB stock #nc82;
Wagh et al., 2006); mouse anti-GluRIIA, 1:200, fixed 5 min in ice-cold
methanol (DSHB stock #8B4D2); rabbit anti-GluRIII, 1:500 (Marrus et
al., 2004); rabbit anti-GluRIII-488, 1:500 (Marrus et al., 2004; Blunk et
al., 2014); anti-Fz2-C, 1:500, and anti-N-terminal fragment of Fz2 (Fz2-
N), 1:100, fixed 10 min in 4% paraformaldehyde (Mathew et al., 2005);
anti-Futsch, 1:50, fixed 30 min in Bouin’s fixative (DSHB stock #22C10;
Fujita et al., 1982; Zipursky et al., 1984); anti-Shank, 1:2000; anti-GFP
Alexa Fluor 488 conjugate, 1:500 (Life Technologies); DyLight 649 con-
jugated anti-horseradish peroxidase, 1:1000 (Jackson Immuno
Research); and Alexa Fluor 488 goat anti-mouse, Alexa Fluor 488 goat
anti-rabbit, and Alexa Fluor 546 goat anti-rabbit, 1:400 (Life Technolo-
gies). Images were acquired with a 40, 1.3 numerical aperture oil-
immersion objective (Carl Zeiss).
Western blot analysis. For quantitative Western blot analysis, larvae
were dissected to remove internal organs and isolate the body wall. Body
walls were lysed in 1 NuPage LDS sample buffer (Life Technologies)
and analyzed by SDS-PAGE. Equal loading was assayed using anti-
tubulin. Western blots were imaged using an Odyssey infrared scanner
(Li-Cor). The signal intensity for each band was measured using Image
Studio (Li-Cor) and normalized to the signal intensity of tubulin. Anti-
bodies were as follows: rabbit anti-GFP, 1:2000 (ab6556; Abcam); mouse
anti-tubulin, 1:20,000 (T5168; Sigma-Aldrich); and IRDye 680LT goat
anti-mouse and IRDye 800CW goat anti-rabbit (Li-Cor).
Internalization of Fz2. The antibody internalization assay was adapted
from previously described procedures (Mathew et al., 2005). Briefly,
samples were dissected in HL3 solution (in mM: 70 NaCl, 5 KCl, 20
MgCl2, 10 NaHCO3, 5 trehalose, 115 sucrose, and 5 HEPES, pH 7.2)
containing 0.1 mM Ca2, and anti-DFz2-N was added (1:100) before
incubation for 2 h at 4°C. Samples were then washed at 4°C in HL3
containing 2 mM Ca2 and shifted to room temperature for 5 min.
Samples were fixed in 4% paraformaldehyde in HL3, washed with PBS,
and incubated with Alexa Fluor 546-conjugated secondary antibody un-
der nonpermeabilizing conditions to label external DFz2. Samples were
then postfixed for 10 min in 4% paraformaldehyde in HL3, permeabil-
ized with PBS containing 0.3% Triton X-100, and incubated with Alexa
Fluor 488-conjugated secondary antibody.
Quantification and statistical analyses of confocal images.Analyses were
conducted using Volocity (version 6.3; PerkinElmer Life and Analytical
Sciences) or FIJI/ImageJ (version 2.0.0-rc-32/1.49v; Schindelin et al.,
2012). Ghost boutons (GBs) were identified by the presence of a presyn-
aptic bouton (HRP-labeled) that lacked Dlg staining in fixed prepara-
tions. Counting of boutons and GBs was conducted at hemisegment A3
atmuscle 6/7, andn refers to the number ofNMJs analyzed,with nomore
than two NMJs analyzed per animal. Measurements of active zone (AZ)
density, GluR intensity, and bouton size were conducted on 12 1b bou-
tons per animal, using one terminal bouton and five adjacent nontermi-
nal boutons, on two different branches; n refers to the number of animals
analyzed. Bouton size was determined by measuring the bouton diame-
ter. AZ density was quantified manually by counting Brp-labeled puncta
and dividing by the volume of HRP. GluR intensity was quantified by
measuring the fluorescence intensity of GluRIII, GluRIIA, or GluRIIB
signal within an ROI defined by theHRP signal, and the average intensity
within the ROI was divided by the average HRP intensity. Glutamate
receptor field size was quantified by manually outlining GluR-labeled
fields and computing volume; n refers to the number of individual GluR-
labeled fields analyzed, with at least six animals analyzed per genotype.
Nuclear import of Fz2-Cwas quantified as described previously (Mathew
et al., 2005), by counting distinct spots of Fz2-C immunoreactivity over
background staining in muscle nuclei. Nucleus boundaries were identi-
fied by costaining with Lamin C (DSHB stock #LC28.26). Fz2-C count-
ing was conducted at hemisegment A3 at muscle 6/7, and n refers to the
number of nuclei counted, with data generated from at least four animals
per genotype. Fz2 internalization was quantified by measuring the fluo-
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rescence intensity of surface or internalized Fz2within anROI defined by
the HRP signal, and the average intensity within the ROI was then nor-
malized to average HRP intensity. Images were captured from hemiseg-
ments A3 and A4 at muscle 6/7, and n refers to the number of NMJs
analyzed, with no more than two NMJs analyzed per animal.
Statistical analyses. Statistical significance in two-way comparisons
was determined by a Student’s t test, whereas ANOVA was used when
comparingmore than two datasets. The p values associatedwithANOVA
tests are adjusted p values obtained from a Tukey’s post hoc test. In all
figures, the data are presented asmean SEM; *p 0.05, **p 0.01, and
***p 0.001 (n.s. indicates not significant). Statistical comparisons are
with control unless noted.
Electronmicroscopy. Sampleswere fixed using aTedPellamicrowave in
1% glutaraldehyde and 4% paraformaldehyde in O.1M cacodylate buf-
fer, pH 7.2. The first round ofmicrowave fixation was at 100W for 1min
on, 1min off, and 1min on (Tapia et al., 2012). Fixation continued at 300
W for 20 s on, 20 s off, and 20 s on, three times. Samples were then
removed from the microwave and fixed in a fresh fixative for 30 min at
room temperature. Samples were washed in 0.1 M cacodylate buffer and
further processed as described previously (Blunk et al., 2014). Quantifi-
cations of SSR andbouton areawere performed inAdobePhotoshopCS4
(Adobe Systems). SSR area was measured by manually outlining the SSR
and bouton and dividing the cross-sectional SSR area by the cross-
sectional bouton area. SSR density was calculated by automatically out-
lining the SSR foldings with PhotoshopMagicWand Tool with tolerance
level 10 and dividing by the SSR area. The boutonmembrane commonly
makes a contact with electron-dense SSR foldings. The length of regions
(200 nm) in which the boutonmembrane was not opposed by SSRwas
calculated in pixels and normalized by bouton perimeter. Each n value
represents a single bouton, with data generated from at least three indi-
vidual larvae of each genotype.
Shank alignment. The Drosophila Shank amino acid sequence was
aligned with human SHANK1, SHANK2, and SHANK3 using Clustal
Omega (version 1.2.1; Sievers et al., 2011).
Quantitative RT-PCR. Quantitative RT-PCR (qPCR) was performed
in triplicate for each of four independent biological replicates per geno-
type. RNA was extracted from three adult male flies per sample using an
RNeasy Mini kit (Qiagen) and treated with DNase I (Qiagen). Single-
stranded cDNA was synthesized using a High Capacity cDNA reverse
transcription kit (Applied Biosystems) according to the protocol of the
manufacturer. Gene-specific transcription levels were determined in a 10
l reaction using SYBR Green Premium Ex TaqII master mix (TaKaRa)
in optical 96-well plates using a LightCycler480 Real Time PCR system
(Roche). Shank primers (5-CCAAATATCCCACGGGTCCG and 5-
GGAGCTGAATGTCTACAAGTGTCTGC) were designed to span the
large first intron, amplifying a 212 bp product from endogenous tran-
script or transcript derived from the UAS–Shank transgene, and separa-
ble from genomic DNA for which the amplicon is 21 kb. Candidate
reference genes and primers (e1F-1A, Rap21, and 14-3-3) were selected
from Ling and Salvaterra (2011). Melt curve analysis was conducted to
ensure primer specificity. A calibration curve was conducted to deter-
mine primer efficiency, by performing qPCR with each primer pair on a
twofold dilution series of control template. The slope of the resulting
standard curve was used to calculate primer efficiency (efficiency 
	1 10 (	1/slope); Shank, 98.0%; e1F-1A, 98.3%;Rap21, 99.83%; and 14-
3-3, 101.78%). Reference genes were analyzed using NormFinder soft-
ware (version 0.953) to determine expression stability (Andersen et al.,
2004). e1F-1A had the lowest stability value (0.005  0.010) as deter-
mined byNormFinder, indicating the highest stability in gene expression
among the candidates, and was selected as the reference gene for relative
quantification. The 2	

C method (Livak and Schmittgen, 2001) was
used to compute Shank gene expression relative to the reference gene,
and data are presented as expression relative to controls (2	

C).
Results
Shank localizes to the postsynaptic membrane
Drosophila Shank (CG30483) is predicted to encode a200 kDa
protein containing several protein–protein interaction motifs,
conserved from invertebrates to humans (Fig. 1A,B). To study
Shank function, we generated antisera against a peptide near the
N terminus of the protein (Fig. 1B). We also produced a null
mutant (ShankD101; Fig. 1A) and a transgenic animal expressing
the full-length cDNAunder control of theUASpromoter, allowing
us to assess synapse development upon loss or overexpression of
Shank. Shank mutants were generated through mobilization of a
Minos transposable element located in the large first intron of the
Shank locus. The resulting ShankD101 allele carries a deletion from
the middle of the first intron to the 3-UTR, removing 97% of the
coding regionof the gene.The sizeof thedeletion, alongwithgenetic
evidence discussed below, indicates that ShankD101 is a null allele. A
precise excision without any deletion was generated from the same
mutagenesis and used as a control.
ShankD101 homozygotes survive to adulthood, allowing exam-
ination of synaptic defects at the third-instar larval NMJ. The
Drosophila larval glutamatergic NMJ consists of an arbor of syn-
aptic boutons innervating amuscle fiber.Within each bouton are
numerous AZs—the sites of neurotransmitter release—that are
apposed by ionotropic glutamate receptor clusters in the postsyn-
aptic cell. Immunostaining for Shank revealed that the protein is
enriched at the NMJ (Fig. 1C). The synaptic enrichment is sub-
stantially reduced in ShankD101 animals (Fig. 1D) and enhanced
on postsynaptic expression of Shank using a muscle GAL4 driver
(mef2Shank; Fig. 1E). We also detected staining of the muscle
nuclei and staining throughout the muscle cytoplasm, which are
unchanged in all genotypes and are thus likely to be nonspecific.
Because the peptide that was used to generate the antisera is de-
leted by the D101 mutation, we interpret any residual staining
seen in ShankD101 animals as nonspecific to Shank. To test
whether Shank localizes to the PSD as it does in mammalian
neurons (Takeuchi et al., 1997), we costained for Dlg, the ho-
molog ofmammalian PSD-95 (Lahey et al., 1994). Shank andDlg
overlap at the synapse, with the Shank domain extending slightly
beyond Dlg (Fig. 1F). We also examined Shank distribution by
overexpressing Shank with a C-terminal GFP tag (mef2Shank–
GFP; Fig. 1G). As observed for the endogenous protein, Shank–
GFP is localized at the NMJ. Shank–GFP also decorates
cytoplasmic puncta, which are not observedwith the endogenous
protein, andmay be a consequence of overexpressing the protein.
Shank regulates synapse morphology and maturity in a dose
dependent manner
To investigate how loss or overexpression of Shank affects synap-
tic development, we quantified the number of boutons per NMJ
at muscle 6/7 in hemisegment A3. ShankD101 animals exhibited a
24% reduction in the number of synaptic boutons compared
with control animals (Fig. 2A,B,I; control, 1.0  0.03, n  48;
ShankD101, 0.76  0.03, n  36, p  0.0001, ANOVA). We also
observed an abnormally high number of structures known asGBs
in ShankD101 mutants (Fig. 2B, arrowheads). GBs are immature
synaptic structures, identified as round varicosities of the presyn-
aptic membrane that lack postsynaptic proteins such as Dlg and
glutamate receptors (Ataman et al., 2006, 2008). ShankD101 ani-
mals exhibited a fourfold increase in the average number of GBs
per NMJ compared with control animals (Fig. 2A,B,J; control,
1.0  0.26, n  31; ShankD101, 3.6  0.74, n  24, p  0.0268,
ANOVA). Thus, Shank is required for normal number and ma-
turity of synaptic boutons.
When ShankD101 was placed in trans to a chromosomal defi-
ciency that removes the entire Shank locus, equivalent defects
were observed compared with ShankD101 homozygous animals
(Fig. 2C,C, I, J; ShankD101/Df, 0.76 0.02 boutons, n 13, p
0.9999, ANOVA; 4.49 1.09 GBs, n 13, p 0.9999, ANOVA).
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This finding is consistent with ShankD101 being a null allele. In-
triguingly, we also detected defects in animals heterozygous for
Shank, with a statistically significant 15% reduction in bouton
number but no increase in GBs, compared with controls (Fig.
2D,D, I, J; ShankD101/, 0.85  0.03 boutons, n  19, p 
0.0110, ANOVA; 0.73 0.21 GBs, n 18, p 0.9999, ANOVA).
Thus, loss of a single copy of Shank is sufficient to produce mild
defects in synapse development.
Figure 1. Shank localizes to the PSD atDrosophilaNMJs.A, Genomic locus of Shank (CG30483). The region deleted in ShankD101 is indicated in red. Coding exons are green, with noncoding exons
in blue.B, The Shank locus encodes a 1871 aa protein predicted to contain Ankyrin repeats (Ank), Src homolgy 3 (SH3), PDZ domains, and a C-terminal coiled-coil motif. The region used to generate
anti-Shank antisera is indicated in red. Shank protein structure is highly conserved compared with human SHANK3. SHANK3 has a proline-rich region and C-terminal SAM domain that are not
conserved in Drosophila Shank. A percentage identity matrix calculated using Clustal Omega is presented comparing Drosophila Shank and human SHANK1, SHANK2, and SHANK3. C–E, Represen-
tative NMJs, stained with antibodies to Shank (green). HRP staining (magenta) marks the neuronal membrane. Arrowheads mark nonspecific staining of the muscle nuclei, which is unchanged in
all genotypes. F, RepresentativeNMJs, stainedwith antibodies to Shank (green) andDlg (magenta).G, RepresentativeNMJs of animals expressingUAS–Shank–GFPwith themef2–GAL4 driver and
stained for GFP (green) and Dlg (magenta). Scale bars: C–F, G, 5m; F, 2m.
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We next overexpressed Shank postsynaptically. Surprisingly,
Shankoverexpression led to phenotypes similar to those observed
in Shank loss of function. When Shank expression was driven
with the strong muscle driver mef2–GAL4 (mef2Shank), the
animals exhibited a 29% reduction in the number of boutons per
NMJ and a sixfold increase in the average number of GBs per
NMJ compared with controls (Fig. 2E,E, I, J; mef2Shank,
0.71 0.03 boutons, n 37, p 0.0001, ANOVA; 6.09 0.96
Figure 2. Shank regulates synaptic morphology and maturity in a dose-dependent manner. A–H, Representative NMJs stained with antibodies to Dlg (magenta) and HRP (green). Bouton number is
decreased in homozygous Shanknullmutants (B), transheterozygotes of the Shanknull allele and a chromosomal deficiency (C), Shankheterozygotes (D), andwith postsynaptic overexpression of Shankwith
mef2–GAL4(E)or24B–GAL4(F ).GBswereidentifiedasroundvaricositiesofHRPstaininglackingDlgstaining.GBnumberis increasedinhomozygousShanknullmutants(B),Shank/Dftransheterozygotes(C),
and during strong postsynaptic overexpression of Shank with mef2–GAL4 (E). Restoration of Shank expression in muscle with a moderate (H, H) but not a strong (G, G) driver rescued the ShankD101
phenotypes. Arrowheads indicateGBs. I, J, Quantificationof total boutonnumber, normalized to the control average (H ), and total GBnumber, normalized to the control average (I ). Gray line indicates control
mean. Data are presented as mean SEM; *p 0.05, **p 0.01, ***p 0.001. n.s., No statistically significant difference. Statistical comparisons are with control unless noted. K, Relative expression
measuredbyqPCR. Individual datapoints represent biological replicates. Shankexpressionwasnormalized to the internal referencegene e1F–1Aand calibrated to control sample. Data arepresentedasmean
2	

C SEM (seeMaterials andMethods). Gray line indicates the calibrated control value ( 1). Scale bars:A–H, 20m;A–H, 10m.
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GBs,n 24, p 0.0001, ANOVA).We also expressed Shankwith
24B–GAL4, a moderate strength muscle driver (24BShank).
These animals exhibited a statistically significant 21% reduction
in the number of boutons per NMJ but no significant increase in
GBs compared with controls (Fig. 2F,F,I,J; 24BShank, 0.79
0.05 boutons, n 19, p 0.0006, ANOVA; 2.08 0.46 GBs, n
19, p 0.9999, ANOVA).
Morphological defects at the NMJ appeared to vary with the
level of Shank expression, with themost severe defects seen in the
genotypes ShankD101 andmef2Shank, in which Shank levels are
expected to be the farthest from control levels. To quantify the
relative expression of Shank across the genotypes, we analyzed
Shank transcripts by qPCR (Fig. 2K). The qPCR results indicated
that the mef2–GAL4 driver produced a large overexpression of
Shank (7.0  1.05-fold) and that the 24B–GAL4 driver produ-
ced a more moderate overexpression (3.1  0.36-fold). Shank
heterozygotes expressed 50% of Shank levels compared with
controls (0.57  0.05-fold). No amplification was detected in
ShankD101 animals. Given the relationship between morphology
and expression level, we hypothesize that Shank function is dose
dependent, with optimal levels of Shank required for normal
synaptic development.
We next attempted to rescue Shankmutant defects by overex-
pressing Shank in Shank null mutants. Expression of Shank with
mef2–GAL4 (ShankD101 mef2Shank) failed to rescue the
morphology defects compared with ShankD101 mutants (Fig.
2G,G, I, J; ShankD101 mef2Shank, 0.69 0.04 boutons, n 18,
p  0.8088, ANOVA; 6.01  1.67 GBs, n  16, p  0.3666,
ANOVA). The qPCR analysis confirmed that Shank transcript
levels remained extremely high in these animals (7.56  0.80-
fold). Thus, it is not surprising that strongmorphological defects
persisted in this genotype. In contrast, expression of Shank with
24B–GAL4 in the ShankD101 background (Fig. 2H,H, I, J;
ShankD101 24BShank, 0.88 0.06 boutons, n 19; 1.64 0.84
GBs, n  17) rescued total bouton number (p  0.0107,
ANOVA) and strongly suppressed GB number (p  0.0182,
ANOVA) compared with ShankD101 mutants. ShankD101
24BShank animals also showed a rescue in bouton number
compared with the defect seen in 24B–GAL4-overexpressing an-
imals (p 0.0378). Comparedwith controls, 24B–GAL4-rescued
animals had fewer boutons (p 0.0398, ANOVA) and a normal
number of GBs (p 0.9999, ANOVA). Thus, moderate expres-
sion of Shank in the ShankD101 background rescued both the
reduction in total bouton number and abnormal excess GB
formation.
Animals expressing Shank presynaptically at the NMJ (with
a neuronal driver; C155Shank) had no morphological ab-
normalities compared with controls (C155Shank, 0.91 
0.03 boutons, n  16, p  0.9999, ANOVA; 1.22  0.45 GBs,
n 16, p 0.9999, ANOVA) and no increase in Shank stain-
ing intensity at the NMJ (data not shown), consistent with a
postsynaptic role for Shank. Furthermore, neuronal expres-
sion of Shank in Shank null mutants (ShankD101 C155Shank)
failed to rescue the morphological defects compared with
ShankD101 mutants (0.65 0.03 boutons, n 12, p 0.9132,
ANOVA; 3.50  1.12 GBs, n  12, p  0.9999, ANOVA).
Thus, our data support the hypothesis that an optimal post-
synaptic Shank concentration is required to support normal
synaptic development, and Shank dosage affects both the
number and maturity of synaptic boutons.
Glutamate receptors and AZs are not affected in
Shank mutants
We next tested whether the organization of neurotransmitter re-
lease sites was affected in Shank mutants by staining for Brp, a
marker of the presynaptic AZ, andGluRIII, an obligate subunit of
the postsynaptic glutamate receptor (Fig. 3A,B). In Shank mu-
tants, AZ density was not significantly different from controls
(Fig. 3I; control, 0.3483  0.02 AZs per volume, n  16;
ShankD101, 0.33  0.01 AZs per volume, n  18, p  0.3706,
Student’s t test). Furthermore, GluRIII clusters were not signifi-
cantly different with respect to size (Fig. 3G: control, 1.55 0.08
m3 per GluR, n 110; ShankD101, 1.68 0.09 m3 per GluR,
n  86, p  0.2487, Student’s t test), or fluorescence intensity
(Fig. 3H; control, 0.86  0.05 GluR per HRP fluorescence, n 
26; ShankD101, 0.78  0.04 GluR per HRP fluorescence, n  26,
p 0.1856, Student’s t test). The apposition of Brp and GluRIII
was also unaffected (Fig. 3A,B).
Glutamate receptors exist in two possible four-subunit
configurations, containing either subunit IIA or IIB, along
with three obligate subunits (IIC/III, IID, and IIE). IIA- and
IIB-containing receptors differ in their functional properties
(DiAntonio et al., 1999), and the incorporation of IIA versus
IIB changes as the PSD matures (Schmid et al., 2008). We
examined GluRIIA (Fig. 3C,D) and GluRIIB (Fig. 3E,F ) in
ShankD101 mutants. We stained for GluRIIA and measured no
statistically significant differences between ShankD101 and
control animals with respect to size (Fig. 3G: control, 1.72 
0.08 m3 per GluR, n 133; ShankD101, 1.52 0.06 m3 per
GluR, n  124, p  0.0521, Student’s t test) or fluorescence
intensity (Fig. 3H: control, 0.34 0.05 GluR per HRP fluores-
cence, n  9; ShankD101, 0.30  0.05 GluR per HRP fluores-
cence, n 10, p 0.5507, Student’s t test) of GluRIIA clusters.
We then assayed GluRIIB by expressing a GFP-labeled
GluRIIB using its endogenous promoter (Schmid et al., 2008)
in control and Shankmutant backgrounds. Similar to what we
observed for GluRIIA and GluRIII, ShankD101 mutants resem-
bled controls with respect to the size (Fig. 3G: control, 1.75
0.10 m3 per GluR, n 129; ShankD101, 1.56 0.07 m3 per
GluR, n  119, p  0.1290, Student’s t test) and fluorescence
intensity (Fig. 3H: control, 0.29 0.03 GluR per HRP fluores-
cence, n  11; ShankD101, 0.24  0.01 GluR per HRP fluores-
cence, n 10, p 0.1213, Student’s t test) of GluRIIB clusters.
Thus, ShankD101 animals did not exhibit defects in the organi-
zation of individual release sites. However, given a normal
density of AZs per bouton (Fig. 3I ) and a decrease in the
number of boutons per NMJ (Fig. 2), Shank mutants had an
overall reduction in the number of neurotransmitter release
sites per NMJ compared with controls.
Shank regulates synaptic ultrastructure
We next examined the synaptic ultrastructure of Shank mu-
tant animals using electron microscopy (Fig. 3 J,K ). Shank
mutants had normal presynaptic ultrastructure (Fig. 3K, red
arrowhead) but exhibited defects in the SSR, a system of mem-
branous infoldings that comprise the postsynaptic membrane
at the NMJ. Because GBs lack SSR completely (Packard et al.,
2002; Ataman et al., 2006), we measured boutons surrounded
by SSR to assess the ultrastructure of more mature terminals.
Loss of Shank resulted in a less complex SSR compared with
controls, with fewer membranous folds (Fig. 3L; control,
0.69 0.02 area of infoldings per SSR area, n 29; ShankD101,
0.56 0.02, n 22, p 0.0001, Student’s t test). Mutants also
had numerous regions of the presynaptic terminal that did not
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contact the SSR compared with controls in which these sur-
faces are typically in close contact (Fig. 3M; control, 0.08 
0.01 SSR-deficient membrane length per bouton perimeter
length, n  30; ShankD101, 0.24  0.03, n  20, p  0.0001,
Student’s t test). The overall area of the SSR was unchanged in
mutants compared with controls (Fig. 3N; control, 3.08 0.29
SSR area per bouton area, n 30; ShankD101, 3.48 0.43, n
20, p 0.4260, Student’s t test). These findings suggest that, in
addition to an increase in immature GBs lacking postsynaptic
specializations, ShankD101 animals also have postsynaptic de-
fects at mature boutons, in which the SSR has fewer infoldings
and makes less contact with the neuronal membrane.
Figure 3. Shank regulates SSR ultrastructure but not AZ organization.A,B, Representative NMJs stainedwith antibodies to GluRIII (green) and Brp (magenta). C,D, Representative NMJs stained
with antibodies to GluRIII (green) and GluRIIA (magenta). E, F, Representative NMJs stained with antibodies to GluRIIB (green) and GluRIII (magenta). Glutamate receptor clusters and AZs appear
normal in Shank null mutants. G–I, Quantification of GluR size (G), GluR fluorescence (H ), and AZ density (I ). J, K, Transmission electronmicroscopy of a bouton and surrounding SSR in control (J )
and ShankD101 (K ). Homozygous Shankmutants have reduced SSR density and gaps between the neuronalmembrane and SSR (black arrowheads). T-bar structure appears normal (red arrowhead).
L–N, Quantification of SSR density, calculated as the area of SSR infoldings normalized to SSR cross-sectional area (L), SSR-deficient neuronal membrane, calculated as the length of neuronal
membranewithout adjacent SSRmembranenormalized to the total boutonperimeter (M ), and cross-sectional SSR area, normalized to bouton area (N ). Data are presented asmean SEM; **p
0.01, ***p 0.001. n.s., Not significant. Scale bars: A–F, 5m; J, K, 200 nm.
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Shank regulates the postsynaptic FNI pathway
Postsynaptic defects, including excess GB formation and abnor-
mal development of the SSR, have been linked to impairment of
the noncanonical Wnt FNI pathway (Packard et al., 2002; Ata-
man et al., 2006; Mosca and Schwarz, 2010; Speese et al., 2012).
Because Shankmutants exhibit similar defects, we tested whether
FNI is affected by perturbation of Shank. One readily observable
step in the FNI pathway is nuclear import of Fz2-C (Mathew et
al., 2005), which occurs after activation of the Fz2 receptor by its
ligand Wg. We examined Fz2-C localization by staining with an
antibody against the Fz2 C terminus (Mathew et al., 2005). Con-
trol animals accumulated Fz2-C puncta in their muscle nuclei as
described previously (Mathew et al., 2005; Fig. 4A,E; 2.24 0.37
puncta per nucleus, n  38). However, the number of nuclear
puncta was significantly decreased in both ShankD101 (Fig. 4B,E;
0.30  0.10 puncta per nucleus, n  30, p  0.0001, ANOVA)
andmef2Shank (Fig. 4C,E; 0.35 0.14 puncta per nucleus, n
23, p  0.0002, ANOVA) compared with controls. This finding
indicates that FNI is impaired after both loss and overexpression
of Shank. Fz2-C was restored in animals expressing Shank with
24B–GAL4 in the ShankD101 background (Fig. 4D,E; 1.46 0.40
puncta per nucleus, n  23) compared with both null mutant
animals (p  0.0359, ANOVA) and mef2Shank animals
(p 0.0421, ANOVA), consistent with the hypothesis that Fz2-C
nuclear import is regulated by Shank and sensitive to Shank
expression.
We next tested whether Shank mutant defects could be res-
cued by expressing an Fz2-C fragment with a nuclear localization
signal (NLS; Mathew et al., 2005). Expression of this transgene
drives Fz2-C into the nucleus, bypassing the FNI pathway, and
rescues postsynaptic defects in FNI pathwaymutants (Mosca and
Schwarz, 2010). Indeed, expression of myc–NLS–Fz2-C with
mef2–GAL4 strongly suppressed the increase in GBs associated
with loss of Shank function (Fig. 4F,G,H,J; control, 1.00 0.04
GBs, n  16; ShankD101, 4.78  1.35 GBs, n  15; ShankD101
mef2Fz2C.nls, 1.34 0.42 GBs, n 22), resulting in a signifi-
cant rescue compared with Shank mutant animals (p  0.0027,
ANOVA). Expression of a control transgene (mef2GFP–NLS)
had no effect (Fig. 4I,J; 3.34  0.85 GBs, n  20, p  0.4710,
ANOVA). These findings support the hypothesis that impair-
ment of FNI underlies the excess GB formation observed in
ShankD101. In contrast, expressing myc–NLS–Fz2-C in the
ShankD101backgrounddid not produce a complete rescue of bou-
ton number compared with Shank mutants (Fig. 4G,H,K;
ShankD101, 0.71  0.03 boutons, n  15; ShankD101
mef2Fz2C.nls, 0.82  0.04 boutons, n  22, p  0.0819,
ANOVA), nor did expression ofGFP–NLS (Fig. 4 I,K; 0.70 0.03
boutons, n  20, p  0.9766, ANOVA). Thus, the size of the
synaptic arbor is likely regulated through additional functions of
Shank at the NMJ.
Wnt signaling at the NMJ is bidirectional, with a presynaptic
canonical pathway that is separable from the postsynaptic FNI
pathway. Mutations of the presynaptic Wnt pathway affect bou-
ton number, size, and presynaptic microtubule organization
(Packard et al., 2002; Ataman et al., 2006; Miech et al., 2008). We
did not detect any defect in bouton size in ShankD101 animals (Fig.
4L; control, 3.77 0.14 m, n 8; ShankD101, 3.69 0.18 m,
n  8, p  0.7466, Student’s t test). We also did not detect any
defects in microtubule organization, determined by staining for
the microtubule-associated protein Futsch (Fig. 4M–O; control,
0.25  0.04% boutons with Futsch loops, n  8; ShankD101,
0.28  0.03% boutons with Futsch loops, n  8, p  0.4084,
Student’s t test). These findings indicate that the presynapticWnt
pathway is not affected during perturbation of Shank.
Shank regulates internalization of Fz2
To investigate how Shank might interact with the FNI pathway,
we tested for colocalization between Shank and the Fz2 receptor.
Examining colocalization of endogenous proteins was not feasi-
ble, because the available antisera are all produced in rabbits.
Therefore, we took two independent approaches: first expressing
Shank–GFP (mef2Shank–GFP) and immunostaining for Fz2
using an antibody against the C terminus (Mathew et al., 2005),
and second expressing Fz2–GFP (mef2Fz2–GFP; Chen et al.,
2004) and immunostaining for Shank. In both cases, we observed
colocalization between Shank and Fz2 at the postsynaptic mem-
brane; both proteins surround the bouton, with the Shank do-
main extending outside of the Fz2 domain and with a region of
overlap between them (Fig. 5A,B). Shank–GFP, Fz2–GFP, and
anti–Fz2 are also found in a punctate pattern in the muscle cyto-
plasm, but we detected no colocalization between Shank and Fz2
on these populations of puncta.
We reasoned that one mechanism by which Shank might reg-
ulate Fz2-C nuclear localization is by affecting the internalization
of Fz2 at the plasmamembrane. To test this model, we measured
surface and internalized Fz2 receptors over timewith an antibody
internalization assay (Mathew et al., 2005; Ataman et al., 2006).
Surface levels of Fz2 were the same among control, ShankD101,
and mef2Shank animals, indicating normal trafficking of the
receptor to the postsynaptic membrane (Fig. 5C–E,G: control,
0.19 0.02 surface Fz2-N, n 8; ShankD101, 0.17 0.01 surface
Fz2-N, n  8; mef2Shank, 0.22  0.03 surface Fz2-N, n  8;
p(control vs ShankD101)  0.7224, ANOVA; p(control vs
mef2Shank)  0.6309, ANOVA). However, we detected a sig-
nificant decrease in ShankD101 in the pool of internalized Fz2 (Fig.
5C,D,F: control, 1.42  0.08 internalized Fz2-N, n  8;
ShankD101, 1.03  0.012 internalized Fz2-N, n  8, p  0.0283,
ANOVA). This evidence suggests that reduced internalization of
the Fz2 receptor is one mechanism by which the FNI pathway is
downregulated in ShankD101 animals. To test whether the total
level of Fz2 protein is affected by Shank, we performed Western
blots on larval body wall extracts from control or ShankD101 ani-
mals expressing Fz2–GFP postsynaptically (Fig. 5H). The level of
Fz2–GFP detected by Western blot was not altered in ShankD101
mutant animals (mef2Fz2–GFP, 1.43  0.15 GFP signal per
tubulin signal,n 4; ShankD101mef2Fz2-GFP, 1.44 0.14GFP
signal per tubulin signal, n 5), indicating that the Fz2 internal-
ization defect measured at the synapse is not attributable to an
indirect role of Shank in the production or degradation of Fz2
protein.
Notably, mef2Shank animals exhibited normal levels of in-
ternalized Fz2 (Fig. 5E,F:mef2Shank, 1.27 0.10 internalized
Fz2-N, n 8, p 0.4883, ANOVA). Thus, downregulation of the
FNI pathway during overexpression of Shankmay occur through
a distinct mechanism. Becausemef2Shank animals lose nuclear
accumulation of Fz2-C, the defect must occur between internal-
ization of the Fz2 receptor and its transport/import into the nu-
cleus. As such, Shank likely acts to organize regulators at the
postsynaptic membrane that both internalize the Fz2 receptor
and mediate its trafficking to the nucleus.
Discussion
By generating Drosophilamutants completely lacking any Shank
protein, we identified a novel function of this synaptic scaffolding
protein in synapse development. We found that aberrant expres-
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sion of Shank results in defects affecting synapse number, matu-
rity, and ultrastructure, and that a subset of these defects is
attributable to a downregulation of a noncanonical Wnt signal-
ing pathway in the postsynaptic cell (Fig. 6).
Shankmutant phenotypes from flies to mammals
The defects we observed in Shankmutants are mostly consistent
with defects described from in vivo and in vitro rodent models of
Shank. Synaptic phenotypes reported from Shank mutants vary,
Figure 4. Shank regulates the postsynaptic FNI pathway. A–D, Representative muscle nuclei stained with antibodies to the C terminus of Fz2. The number of Fz2-C puncta (red arrowheads) is
reduced with homozygous loss of Shank (B) or postsynaptic overexpression of Shank (C). The ShankD101 mutant defect is rescued by postsynaptic overexpression of Shank with 24B–GAL4 (D). E,
Quantification of Fz2-C puncta per nucleus. F–I, Representative NMJs stained with antibodies to Dlg (magenta) and HRP (green). Expression of Fz2-C.nls gives a strong rescue of the Shank GB
phenotype (H, H). Expression of GFP.nls has no rescue effect (I, I). Arrowheads indicate GBs. J, K, Quantification of GB number, normalized to the control average (J ), and total bouton number,
normalized to the control average (K ). Gray line indicates controlmean. L, Quantification of bouton size.M, Quantification of Futsch loops.N–O, RepresentativeNMJs stainedwith Futsch to visualize
microtubules. Arrowheads indicate Futsch loops. Data are presented as mean SEM; *p 0.05, **p 0.01, ***p 0.001. n.s., Not significant. Statistical comparisons are with control unless
noted. Scale bars: A–D, 5m; F–I, N, O, 20m; F–I, N, O, 10m.
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likely reflecting incomplete knockdown of Shank splice variants,
and heterogeneity in the requirement for Shank between the dif-
ferent brain regions and developmental stages analyzed (for re-
view, see Jiang and Ehlers, 2013). Nevertheless, taken collectively,
analyses of Shank1–Shank3 mutant mice indicate that Shank
genes regulate multiple parameters of the structure and function
of glutamatergic synapses, including themorphology of dendritic
spines and the organization of proteins in the PSD (Hung et al.,
2008; Bozdagi et al., 2010; Pec¸a et al., 2011; Wang et al., 2011;
Schmeisser et al., 2012; Won et al., 2012; Kouser et al., 2013;
Speed et al., 2015).
By removing all Shank protein in Drosophila, we identified
essential functions for Shank at a model glutamatergic syn-
apse. Shankmutants exhibit prominent abnormalities in synaptic
structure, including a decrease in the total number of synaptic
boutons, which results in an overall decrease in the number of
AZs. In addition, a subset of synaptic boutons fails to assemble a
postsynaptic apparatus. Finally, even inmature boutons, the SSR
has fewer membranous folds and makes less frequent contact
with the presynaptic membrane, indicating a defect in postsyn-
aptic development. The SSR houses and concentrates important
synaptic components near the synaptic cleft, including scaffold-
Figure 5. Shank regulates internalization of Fz2.A, Representative NMJ froman animal expressing Fz2–GFP (green) stainedwith antibodies to Shank (magenta).B, Representative NMJ froman
animal expressing Shank–GFP (magenta) stainedwith antibodies to Fz2-C (green). C–E, Representative NMJs stained to label the internalized pool (green) and surface pool (magenta) of Fz2, with
an antibody against an extracellular epitope in the N terminus. ShankD101 animals exhibited a reduction in the internalized pool of Fz2 (D). F,G, Quantification of internalized Fz2, normalized to HRP
signal (F ), and surface Fz2, normalized to HRP signal (G). H, Western blot and quantification of body wall muscle extracts from control animals (the UAS–Fz2–GFP line with no driver), animals
expressing Fz2–GFP (mef2Fz2–GFP), and ShankD101 animals expressing Fz2–GFP (ShankD101 mef2Fz2–GFP), probed for GFP and tubulin (Tub; loading control). The level of expression of
Fz2–GFP is not affected in the ShankD101mutant background. Data are presented asmean SEM; *p 0.05. n.s., Not significant. Statistical comparisons arewith control unless noted. Scale bars:
A, B, 5m; C–E, 10m.
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ing proteins, adhesionmolecules, and glutamate receptors. Thus,
defects in SSR development can affect the assembly and regula-
tion of synaptic signaling platforms. Our findings indicate that
Shank is a key regulator of synaptic growth and maturation.
Gene dosage of Shank
Our findings also indicate that gene dosage of Shank is critical for
normal synapse development at Drosophila glutamatergic NMJs.
The morphological phenotypes we observe scale with the level of
Shank expression, with mild phenotypes seen with both 50% loss
and moderate overexpression of Shank, and severe phenotypes
seen with both full loss and strong overexpression of Shank (Fig.
6). The observation of synapse loss in heterozygotes of the Shank
null allele is significant, because haploinsufficiency of SHANK3 is
well established as a monogenic cause of ASD (Betancur and
Buxbaum, 2013).
Consistent with the observation that excess Shank is detri-
mental, duplications of the SHANK3 genomic region (22q13) are
known to cause a spectrum of neuropsychiatric disorders. Large
duplications spanning SHANK3 and multiple neighboring genes
have been reported in individuals with attention deficit–hyper-
activity disorder (ADHD), schizophrenia, and ASD (Durand et
al., 2007; Failla et al., 2007; Moessner et al., 2007). Smaller dupli-
cations, spanning SHANK3 and only one or two adjacent genes,
have been reported in individuals with ADHD, epilepsy, and bi-
polar disorder (Han et al., 2013). Furthermore, duplication of the
Shank3 locus inmice results inmanic-like behavior, seizures, and
defects in neuronal excitatory/inhibitory balance (Han et al.,
2013). Thus, the requirement for proper Shank dosage for nor-
mal synaptic function may be a conserved feature.
Shank as a regulator of synapse-to-nucleusWnt signaling
One unexpected finding from our study was the identification of
a previously unappreciated aspect of Shank as a regulator of Wnt
signaling. Shank regulates the internalization of the transmem-
brane Fz2 receptor, thus affecting transduction of Wnt signaling
from the plasma membrane to the nucleus. Downregulation of
this pathway is implicated in impaired postsynaptic organization,
including supernumerary GBs and SSR defects (Ataman et al.,
2006; Mosca and Schwarz, 2010). The physical proximity of
Shank and Fz2 at the postsynapticmembrane suggests that Shank
directly or indirectly modulates the internalization of Fz2. Shank
is a scaffolding protein with many binding partners that could
contribute to such an interaction (Jiang and Ehlers, 2013). One
intriguing possibility is the PDZ-containing protein Grip.
Shank2 and Shank3 have been reported to bindGrip1 (Sheng and
Kim, 2000; Uemura et al., 2004). Furthermore, Drosophila Grip
transports Fz2 to the nucleus on microtubules to facilitate the
FNI pathway (Ataman et al., 2006). Thus, an interaction between
Shank, Fz2, andGrip to regulate synaptic signaling is an attractive
model.
Although loss of Shank is associated with impaired internal-
ization of the Fz2 receptor, how excess Shank leads to FNI im-
pairment remains an open question. One possibility is that an
increase in the concentration of the Shank scaffold at the synapse
physically impedes the transport of Fz2 or other components of
the pathway or saturates binding partners that are essential for
Fz2 trafficking. Both overexpression and loss of function of
Shank ultimately lead to a failure to accumulate the cleaved Fz2 C
terminus within the nucleus, in which it is required to interact
with RNA binding proteins that facilitate transport of synaptic
transcripts to postsynaptic compartments. Although Shank and
Wnt both play important synaptic roles, this study is the first
demonstration of a functional interaction between Shank and
Wnt signaling at the synapse.
Shank as a regulator of glutamate receptors
Intriguingly, we find no obvious defects in glutamate receptor
levels or distribution in the absence of Shank. This was surprising
given the role for Shank in regulating the FNI pathway, and
downregulation of FNIwas shown previously to lead to increased
GluR field size (Speese et al., 2012). Several studies have reported
changes in the levels of AMPA or NMDA receptor subunits in
Shankmutant mice (Bozdagi et al., 2010; Pec¸a et al., 2011; Wang
et al., 2011; Verpelli et al., 2012), although others have also ob-
served no changes (Verpelli et al., 2011; Kouser et al., 2013; Speed
et al., 2015). Levels of metabotropic glutamate receptors are also
affected in some Shank mutant models (Verpelli et al., 2011;
Kouser et al., 2013). Moreover, transfected Shank3 can recruit
functional glutamate receptors in cultured cerebellar neurons
(Roussignol et al., 2005). It is possible that Drosophila Shank
mutants have defects in GluRs that are too subtle to detect with
our current methodology. Another possibility is that Shank is
involved in signaling mechanisms that are secondary to FNI and
Figure 6. Model of Shank function. A, Shank functions in a dose-dependent manner to regulate multiple parameters of synapse biology. Both partial loss and partial overexpression of Shank
(blue) result in a reduction in the number of synapses at theNMJ. Very lowand very high levels of Shank (purple) produce both synapse number defects and synapsematuration defects. The synapse
maturation defects are associated with downregulation of FNI signaling. In Shank mutants, the mechanism of FNI downregulation is an impairment of Fz2 internalization from the membrane,
whereas for high Shank overexpression, FNI impairment occurs by a differentmechanism.B, Shank localizes to the postsynaptic membrane in which it regulates internalization of theWnt receptor
Fz2 to regulate synapse maturation. In the FNI signaling pathway, Fz2 is subsequently transported on microtubules and cleaved, and Fz2-C is imported into the nucleus to regulate synaptic
transcription.
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that lead to compensatory changes in GluRs at individual syn-
apses. Indeed, our results are consistent with Shank having addi-
tional functions at the synapse in addition to its role in FNI,
particularly affecting synaptic bouton number. In conclusion, we
find that the soleDrosophila Shankhomolog functions to regulate
synaptic development in a dose-dependent manner, providing a
newmodel system to further investigate how loss of this scaffold-
ing protein may underlie neurodevelopmental disease.
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